Custodes Futurifor the advancement of humanity

Substance use

Substance use is a barrier to human progress within the biological factors. The evidence for it, and the methods proposed to address it, follow.

Addictive substances act on the brain circuits for reward and decision-making. They can shift behavior toward short-term relief.

Evidence

  • Scale. WHO (2024) estimated that alcohol caused 2.6 million deaths in 2019 (4.7% of all deaths). WHO estimated that drugs caused 0.6 million. About 400 million people had alcohol use disorders, including 209 million with alcohol dependence.
  • Adolescent cannabis use. Researchers combined three Australian and New Zealand cohorts (3,765 people). Those who used cannabis daily before age 17 had about 63% lower odds of finishing high school than those who never used it. They also had 62% lower odds of earning a degree. These results held after adjusting for many background factors (Silins et al., 2014).
  • Causation. Whether cannabis causes this or marks earlier disadvantage is debated. A published letter noted that daily users did no worse than weekly users on schooling.

What can be done

Actions rated on the strength-rating scale (A strong and replicated, B solid but limited, C weak or debated, D contested or failed), applied to the specific claim made.

  • Alcohol taxes (A). Across 112 studies, higher prices consistently reduced drinking (Wagenaar, Salois, and Komro, 2009).
  • Minimum unit pricing for alcohol (B). In Scotland, deaths wholly attributable to alcohol fell 13.4%. The largest gains were in the poorest areas (Wyper et al., 2023).
  • Limits on hours of alcohol sale (B). Extending on-premises sale hours by two or more raised alcohol-related harms (U.S. Community Preventive Services Task Force).
  • Opioid agonist treatment such as methadone (A for staying in treatment and reducing heroin use). Methadone did better than approaches without medication (Mattick et al., 2009). In cohort studies, unadjusted death rates were 3.2 times higher out of treatment than in it (C) (Sordo et al., 2017).
  • Brief alcohol advice in primary care (A, small effect). Across 69 trials, people drank about 20 grams less alcohol per week a year later (Kaner et al., 2018).
  • Naloxone distribution (C, observational). In Massachusetts, opioid overdose death rates were lower in communities with more naloxone training (Walley et al., 2013).
  • School and community prevention (B, small effects). School programs that combine social skills with resisting peer influence cut later cannabis use by 17% (Faggiano et al., 2014). Communities That Care raised lifetime abstinence by grade 12. But it did not lower current use (Hawkins et al., 2014). The Good Behavior Game reduced later drug problems in Baltimore boys (Kellam et al., 2008). But an English trial did not replicate its effect on disruptive behavior (Troncoso and Humphrey, 2021).
  • Not effective or unproven: DARE had no effect on drug use (A for no effect) (West and O'Neal, 2004). There is no robust evidence either way on alcohol advertising bans (C) (Siegfried et al., 2014). The Icelandic prevention model has no randomized trial. The EU drug agency rates it "additional studies recommended" (C) (EUDA).
  • Context: In the United States, recreational cannabis legalization has been linked to modest increases in youth use. Medical legalization has not (C) (Pawar et al., 2024).

Proposed and experimental methods

Methods that are proposed, under trial, approved in some places, or tried and then failed. Each shows a stage label and an evidence rating. A stage label shows how far a method has progressed, not whether it works. The stage labels are explained on the biological factor page.

  • GLP-1 drugs for alcohol and opioid use disorders (Early trial, B). This uses semaglutide and similar drugs to reduce drinking and drug use. These drugs appear to dampen the brain's reward response. In a 48-person phase 2 trial, low-dose semaglutide reduced alcohol drunk in a laboratory test, drinks per drinking day, and craving. In that trial, the drug did not reduce drinks per day or the number of drinking days (Hendershot et al., 2025). A 26-week trial included 108 people with alcohol use disorder and obesity. In that trial, weekly semaglutide added to cognitive behavioral therapy cut heavy drinking days by 13.7 percentage points more than placebo (Klausen et al., 2026). Another study used U.S. health records of 503,747 people with opioid use disorder and 817,309 with alcohol use disorder. In those records, GLP-1 or GIP prescriptions were associated with lower rates of opioid overdose (aIRR 0.60) and alcohol intoxication (aIRR 0.50). But such data cannot rule out other explanations (Qeadan et al., 2025).
  • Psilocybin-assisted therapy for alcohol use disorder (Early trial, B). This combines two high-dose psilocybin sessions with talk therapy. A trial included 95 adults. In that trial, heavy drinking days over 32 weeks were 9.7% with psilocybin versus 23.6% with an active placebo (diphenhydramine). That is a 13.9 point difference (95% CI 3.0 to 24.7) (Bogenschutz et al., 2022). This is a single trial, and 78.9% of participants were non-Hispanic White.
  • Very low nicotine standard for cigarettes (Large trial, B). This cuts the nicotine in cigarettes to levels too low to sustain addiction. A 6-week trial included 840 smokers. In that trial, cigarettes with 0.4 mg of nicotine per gram of tobacco cut smoking to 14.9 cigarettes per day, versus 22.2 with usual brands. The trial found little sign of compensatory smoking (Donny et al., 2015). The FDA proposed a cap of 0.70 mg per gram on January 16, 2025. The FDA modeled that more than 12.9 million additional people would quit in the first year. The FDA also modeled that 4.3 million deaths would be averted by the end of the century (FDA, 2025). The government's Spring 2025 regulatory agenda lists the proposal as withdrawn on April 21, 2025 (OIRA, 2025). But no withdrawal notice or final rule had appeared in the Federal Register as of October 9, 2026 (Federal Register, 2026). A maker of low-nicotine cigarettes is urging the FDA to act (22nd Century Group, 2026).
  • Supervised consumption sites, also called overdose prevention centers (Approved but not scaled, B). At these sites, people use drugs they already have under supervision, with naloxone on hand. The first two sanctioned U.S. sites opened in New York City in November 2021. A study compared them with areas around 17 syringe service programs. The study found the sites were not associated with changes in violent or property crime, 911 calls, or 311 complaints. The study also found that drug possession arrests nearby fell 82.7%. The authors linked this fall to police easing enforcement in line with city support for the sites (Chalfin et al., 2023).
  • Generational tobacco sales ban (Approved but not scaled, contested, C). This bans tobacco sales to anyone born after a set date, so the legal age for buying tobacco rises every year. The UK Tobacco and Vapes Act received royal assent on 29 April 2026. Under the Act, nobody born on or after 1 January 2009 can be sold tobacco (Hart and Caddy, 2026). The ban comes into force on 1 January 2027 (ASH, 2026). New Zealand passed a similar law. New Zealand then repealed the law under urgency, together with its retailer reduction and denicotinization measures, before any of them took effect (1News Reporters, 2024). The repeal became law on 5 March 2024 (New Zealand Parliament, 2024). No health outcome data were found.
  • Safer supply, prescribed pharmaceutical alternatives (Approved but not scaled, contested, D). This means prescribing pharmaceutical opioids or stimulants to people at high risk of poisoning from the illegal drug supply. A study looked at 5,882 people in British Columbia. In that study, receiving prescribed opioids in a given week was associated with lower all-cause death (aHR 0.39) and overdose death (aHR 0.45). The study found larger effects at four or more days per week (Slaunwhite et al., 2024). A province-level comparison found the policy was associated with 3.2 more opioid poisoning hospitalizations per 100,000 people and no significant change in deaths (Nguyen et al., 2024). In February 2025 British Columbia moved the program from take-home doses to witnessed consumption, citing diversion of the drugs (Judd, 2025).
  • Failed: Vaccines against addictive drugs (Failed or reversed, A for no effect). These vaccines make the body produce antibodies that bind nicotine or cocaine, so less reaches the brain. A Cochrane review of four trials with 2,642 smokers found no evidence that nicotine vaccines improve long-term quitting. In the same review, two phase 3 NicVAX trials reported quit rates of about 11% in both groups (Hartmann-Boyce et al., 2012). A phase 3 cocaine vaccine trial in 300 people found no significant difference in cocaine-positive urine samples over 16 weeks (Kosten et al., 2014).
  • Reversed: Drug decriminalization, Oregon Measure 110 (Failed or reversed, contested, D). This replaced criminal penalties for possessing small amounts of drugs with civil fines and treatment funding. The change was in effect from February 1, 2021. One synthetic control study (which compares the state with a weighted mix of similar states) found no association with fatal overdose rates in the first year (Joshi et al., 2023). Another study estimated 182 extra overdose deaths in 2021, a 23% increase (Spencer, 2023). A third study found that a crude increase disappeared once the arrival of fentanyl was taken into account (estimate -0.51, P = .41) (Zoorob et al., 2024). Oregon made possession a misdemeanor again through House Bill 4002, signed on April 1, 2024. New charges started September 1 of that year (Wilson, 2024).

Sources cited on this page

  1. Silins, E., Horwood, L. J., Patton, G. C., et al. (2014). Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry, 1(4), 286-293. DOI B Moderate: for the association, C for causation
  2. WHO: Congenital disorders fact sheet (2023) B Moderate
  3. WHO: Nearly 1.8 billion adults not doing enough physical activity (2024) B Moderate: agency estimate
  4. Faggiano, F., Minozzi, S., Versino, E., & Buscemi, D. (2014). Universal school-based prevention for illicit drug use. Cochrane Database of Systematic Reviews, 2014(12), CD003020. link B Moderate
  5. Hawkins, J. D., Oesterle, S., Brown, E. C., Abbott, R. D., & Catalano, R. F. (2014). Youth problem behaviors 8 years after implementing the Communities That Care prevention system: A community-randomized trial. JAMA Pediatrics, 168(2), 122-129. link B Moderate
  6. Humphrey, J. H., Mbuya, M. N. N., Ntozini, R., Moulton, L. H., Stoltzfus, R. J., Tavengwa, N. V., et al. (SHINE Trial Team). (2019). Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting and anaemia in rural Zimbabwe: A cluster-randomised trial. The Lancet Global Health, 7(1), e132-e147. link A Strong
  7. Kaner, E. F. S., Beyer, F. R., Muirhead, C., Campbell, F., Pienaar, E. D., Bertholet, N., et al. (2018). Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database of Systematic Reviews, 2018(2), CD004148. link A Strong
  8. Kellam, S. G., Brown, C. H., Poduska, J. M., Ialongo, N. S., Wang, W., Toyinbo, P., et al. (2008). Effects of a universal classroom behavior management program in first and second grades on young adult behavioral, psychiatric, and social outcomes. Drug and Alcohol Dependence, 95(Suppl. 1), S5-S28. link B Moderate
  9. Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, 2009(3), CD002209. link A Strong: for retention and heroin use
  10. Neal, B., Wu, Y., Feng, X., Zhang, R., Zhang, Y., Shi, J., et al. (2021). Effect of salt substitution on cardiovascular events and death. New England Journal of Medicine, 385(12), 1067-1077. link B Moderate
  11. Pawar, A. K. S., Firmin, E. S., Wilens, T. E., & Hammond, C. J. (2024). Systematic review and meta-analysis: Medical and recreational cannabis legalization and cannabis use among youth in the United States. Journal of the American Academy of Child and Adolescent Psychiatry, 63(11), 1084-1113. link C Limited
  12. Siegfried, N., Pienaar, D. C., Ataguba, J. E., Volmink, J., Kredo, T., Jere, M., & Parry, C. D. H. (2014). Restricting or banning alcohol advertising to reduce alcohol consumption in adults and adolescents. Cochrane Database of Systematic Reviews, 2014(11), CD010704. link C Limited
  13. Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357, j1550. link C Limited
  14. Troncoso, P., & Humphrey, N. (2021). Playing the long game: A multivariate multilevel non-linear growth curve model of long-term effects in a randomized trial of the Good Behavior Game. Journal of School Psychology, 88, 68-84. link B Moderate
  15. Wagenaar, A. C., Salois, M. J., & Komro, K. A. (2009). Effects of beverage alcohol price and tax levels on drinking: A meta-analysis of 1003 estimates from 112 studies. Addiction, 104(2), 179-190. link A Strong
  16. Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ruiz, S., & Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. BMJ, 346, f174. link C Limited
  17. West, S. L., & O'Neal, K. K. (2004). Project D.A.R.E. outcome effectiveness revisited. American Journal of Public Health, 94(6), 1027-1029. link A Strong
  18. Wilson, P., Rush, R., Hussey, S., Puckering, C., Sim, F., Allely, C. S., Doku, P., McConnachie, A., & Gillberg, C. (2012). How evidence-based is an "evidence-based parenting program"? A PRISMA systematic review and meta-analysis of Triple P. BMC Medicine, 10, 130. link B Moderate
  19. Wyper, G. M. A., Mackay, D. F., Fraser, C., Lewsey, J., Robinson, M., Beeston, C., & Giles, L. (2023). Evaluating the impact of alcohol minimum unit pricing on deaths and hospitalisations in Scotland: A controlled interrupted time series study. The Lancet, 401(10385), 1361-1370. link B Moderate
  20. Hartman, S. J., Hibberd, M. C., Mostafa, I., Naila, N. N., Islam, M. M., Zaman, M. U., et al. (2024). A microbiome-directed therapeutic food for children recovering from severe acute malnutrition. Science Translational Medicine, 16(767), eadn2366. link B Moderate
  21. Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., et al. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 79(10), 953-962. link B Moderate
  22. Chalfin, A., del Pozo, B., & Mitre-Becerril, D. (2023). Overdose prevention centers, crime, and disorder in New York City. JAMA Network Open, 6(11), e2342228. link B Moderate
  23. Donny, E. C., Denlinger, R. L., Tidey, J. W., Koopmeiners, J. S., Benowitz, N. L., Vandrey, R. G., et al. (2015). Randomized trial of reduced-nicotine standards for cigarettes. New England Journal of Medicine, 373(14), 1340-1349. link B Moderate
  24. Hart, H., & Caddy, P. (2026, May 7). Tobacco and Vapes Act 2026 becomes law. Lewis Silkin. link B Moderate
  25. Hartmann-Boyce, J., Cahill, K., Hatsukami, D., & Cornuz, J. (2012). Nicotine vaccines for smoking cessation. Cochrane Database of Systematic Reviews, 2012(8), CD007072. link A Strong
  26. Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., et al. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 82(4), 395-405. link B Moderate
  27. Joshi, S., Rivera, B. D., Cerdá, M., Guy, G. P., Strahan, A., Wheelock, H., & Davis, C. S. (2023). One-year association of drug possession law change with fatal drug overdose in Oregon and Washington. JAMA Psychiatry, 80(12), 1277-1283. link B Moderate
  28. Judd, A. (2025, February 19). B.C. overhauls safe supply program, moving to witnessed model. Global News. link B Moderate
  29. Klausen, M. K., Justesen, S. K., Pedersen, J. N., Rasmussen, L., Jensen, A., Jensen, M. E., et al. (2026). Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double-blind, placebo-controlled trial. The Lancet, 407(10540), 1687-1698. link B Moderate
  30. Kosten, T. R., Domingo, C. B., Shorter, D., Orson, F., Green, C., Somoza, E., et al. (2014). Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial. Drug and Alcohol Dependence, 140, 42-47. link B Moderate
  31. Nguyen, H. V., Mital, S., Bugden, S., & McGinty, E. E. (2024). British Columbia's Safer Opioid Supply policy and opioid outcomes. JAMA Internal Medicine, 184(3), 256-264. link C Limited
  32. Qeadan, F., McCunn, A., & Tingey, B. (2025). The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction, 120(2), 236-250. link C Limited
  33. Slaunwhite, A., Min, J. E., Palis, H., Urbanoski, K., Pauly, B., Barker, B., et al. (2024). Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: Retrospective cohort study. BMJ, 384, e076336. link C Limited
  34. Spencer, N. (2023). Does drug decriminalization increase unintentional drug overdose deaths? Early evidence from Oregon Measure 110. Journal of Health Economics, 91, 102798. link D Contested
  35. Wilson, C. (2024, April 1). Oregon governor signs bill criminalizing drug possession. Oregon Public Broadcasting. link B Moderate
  36. Zoorob, M. J., Park, J. N., Kral, A. H., Lambdin, B. H., & del Pozo, B. (2024). Drug decriminalization, fentanyl, and fatal overdoses in Oregon. JAMA Network Open, 7(9), e2431612. link B Moderate

Every source for this factor is listed on the biological factor page.